Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.
Postmortem studies have associated Alzheimer's disease (AD) with regionally increased oxidative damage to brain. Lacking, however, is a specific marker of oxidative damage to brain that may be measured during life. We tested the hypothesis that cerebrospinal fluid (CSF) concentrations of F2-isoprostanes (F2-IsoPs), stable products of arachidonate peroxidation, are increased in CSF of AD patients. CSF from lateral ventricles (VF) was analyzed from 11 AD patients and 11 control subjects who participated in a rapid autopsy program. VF F2-IsoP concentrations were significantly elevated in AD patients compared with control subjects (72 +/- 7 vs 46 +/- 4 pg/ml) and were significantly linearly correlated with brain weight (-0.3 pg/ml/g, r2 = 0.32). These results suggest that quantification of CSF F2-IsoP concentrations may provide a useful biomarker of central nervous system oxidative damage in AD.
Montine
T J
TJ
Department of Pathology, and Center for Molecular Neurosciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Markesbery
W R
WR
Morrow
J D
JD
Roberts
L J
LJ
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D015415:Biomarkers / Q000134:cerebrospinal fluid; D015237:Dinoprost / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male
D015415:Biomarkers; D015237:Dinoprost